NCT07073014
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Enrolling by Invitation
PHASE3All AgesInterventionalTreatmentBioMarin Pharmaceutical
~140 participants
Updated 2025-07-18 on ClinicalTrials.gov
What's tested:Vosoritide
At a glance
Recruiting sites
0 of 23 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate the long-term efficacy of vosoritide treatment until final adult height (FAH)
Measured over Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males
Conditions
Where it's being run
23 sites across 14 statesFrance4
Japan4
Italy3
Germany2
Delaware1
District of Columbia1
Illinois1
Wisconsin1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participants must have completed the Week 52 visit for 111-303 or 111-212 and have open epiphyses as assessed by left hand antero-posterior (AP) X-rays
Parent(s) or guardian(s) must be willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any study-related procedure
Females ≥ 10 years old or who have begun menses must have a negative pregnancy test at the Baseline visit and be willing to have additional pregnancy tests during the study
If sexually active, participants must be willing to use a highly effective method of contraception while participating in the study
Participants are willing and able to perform all study procedures as physically possible
Parent(s) or caregiver(s) are willing to administer daily injections to the participants and willing to complete the required training
Exclusion
Permanently discontinued study treatment in the studies 111-303 or 111-212
Evidence of decreased growth velocity (AGV \< 1.5 cm/year) as assessed over a period of at least 6 months and growth plate closure assessed as per standard of care
Taking or planning to take any prohibited medications
Planned or expected to have limb-lengthening surgery during the study period
Planned or expected bone-related surgery during the study period
Require any investigational agent prior to completion of study period
Have current malignancy, history of malignancy, or currently under work-up for suspected malignancy
Have known hypersensitivity to vosoritide or its excipients
Is pregnant or breastfeeding at Baseline or planning to become pregnant (self or partner) at any time during the study
Concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason
What this trial measures
- Evaluate the long-term efficacy of vosoritide treatment until final adult height (FAH)Annually from enrollment through Final Adult Height, defined as 16 years of age for females and 18 years of age for males
As measured by change from baseline in height Z-score